V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Esperion Therapeutics Executive Compensation (FY25)

ESPR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Sheldon Koenig
Latest say-on-pay support
=
May 28, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Esperion Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 1, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Esperion Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
230 figures on this page: 220 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sheldon Koenig: $3,175,240 → $3,535,512 (11.3% higher)
Say-on-pay support: 72.6% → 73.3% (0.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Esperion Therapeutics' chief executive and what were they paid?
Total compensation for Sheldon Koenig, President and Chief Executive Officer, came to $3,535,512 in fiscal 2025. Compared with the $3,175,240 reported for fiscal 2024, Koenig's total was 11.3% higher.
What was Esperion Therapeutics' say-on-pay result?
The say-on-pay proposal drew 73.3% of votes cast for or against in favor at the meeting held May 28, 2026 for fiscal 2025.
Which companies are in Esperion Therapeutics' peer group?
Companies named in the disclosed peer group include Aadi Bioscience, Inc., Akebia Therapeutics, Inc., Aquestive Therapeutics, Inc., Ardelyx, Inc. and Cara Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
JoAnne Foody
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
JoAnne Foody
Chief Medical Officer
◇—◇◇◇—◇◇
Eric Warren
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
JoAnne Foody
Chief Medical Officer
◇—◇◇◇—◇◇
Benjamin Halladay
Chief Financial Officer
◇—◇◇◇—◇◇
Eric Warren
Chief Commercial Officer
◇—◇◇◇—◇◇
Benjamin Looker
General Counsel
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
John Harlow
Chief Commercial Officer
◇◇◇◇——◇◇
Benjamin Halladay
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Benjamin HalladayOTHER——————◇
Benjamin HalladayOPTION——————◇
John HarlowOPTION——————◇
John HarlowOTHER——————◇
Sheldon KoenigOPTION——————◇
Sheldon KoenigOTHER——————◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Benjamin HalladayRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Sheldon KoenigRSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
John HarlowRSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Benjamin Halladay
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
John Harlow
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Sheldon Koenig
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
J. Martin Carroll
Board chair
◇◇◇———◇
Seth H.Z. Fischer
◇◇◇———◇
Tracy M. Woody
◇—◇———◇
Jay P. Shepard
◇◇◇———◇
Stephen Rocamboli
◇◇◇———◇
Robert E. Hoffman
◇◇◇———◇
Nicole Vitullo
◇—◇———◇
Antonio M. Gotto, Jr., M.D., D.Phil
◇————◇◇
Alan Fuhrman
◇—————◇
Craig Thompson
◇—◇———◇
Sheldon L. Koenig served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Aadi Bioscience, Inc. AADI
  • Akebia Therapeutics, Inc. AKBA
  • Aquestive Therapeutics, Inc. AQST
  • Ardelyx, Inc. ARDX
  • Cara Therapeutics, Inc. CARA
  • EyePoint Pharmaceuticals, Inc. EYPT
  • G1 Therapeutics, Inc. GTHX
  • Intercept Pharmaceuticals, Inc. ICPT
  • Karyopharm Therapeutics, Inc. KPTI
  • Omeros Corporation OMER
  • OptiNose, Inc. OPTN
  • Paratek Pharmaceuticals, Inc. ENTA
  • Puma Biotechnology, Inc. PBYI
  • Rigel Pharmaceuticals, Inc. RIGL
  • Vanda Pharmaceuticals, Inc. VNDA
  • Xeris Biopharma Holdings XERS
  • Y-mAbs Therapeutics, Inc. YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 28, 2026=◇◇◇
2024May 29, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2020May 27, 2021=◇◇◇
2019May 28, 2020=◇◇◇
2018May 29, 2019=◇◇◇
2017May 23, 2018=◇◇◇
2016April 17, 2017=◇◇◇
2015June 9, 2016=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sheldon Koenig (President and Chief Executive Officer), FY2025 total compensation $3,535,512 (base salary $770,833) [exec_comp, SEC accession 0001628280-26-025499, filed 2026-04-16]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Esperion Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Esperion Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Esperion Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Esperion Therapeutics' disclosed peer group is defensible, who names Esperion Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
230 figures on this page: 220 cited to the filing that reported them, 10 calculated from figures it prints.
220 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001628280-26-039518
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-025499
    2025 Director Compensation Table · 2025 Summary Compensation Table · Compensation Discussion and Analysis · EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · and 1 more section
  3. 0001628280-25-028820
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-018229
  5. 0001628280-24-025418
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001628280-24-015824
  7. 0001628280-23-022276
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001628280-21-011340
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-20-067802
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001104659-19-032758
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-18-036428
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-17-024913
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001104659-16-127351
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Esperion Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ESPR (accessed 2026).
Short form: data: Velarion

The Esperion Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Esperion Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Esperion Therapeutics discloses

The companies named in ESPR's own disclosed peer group.

Akebia Therapeutics, Inc.Aquestive Therapeutics, Inc.Ardelyx, Inc.Cara Therapeutics, Inc.EyePoint Pharmaceuticals, Inc.G1 Therapeutics, Inc.Intercept Pharmaceuticals, Inc.Karyopharm Therapeutics, Inc.Omeros CorporationOptiNose, Inc.Paratek Pharmaceuticals, Inc.Puma Biotechnology, Inc.Rigel Pharmaceuticals, Inc.Vanda Pharmaceuticals, Inc.Xeris Biopharma HoldingsY-mAbs Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy